Recently, Elevation Oncology, a company focused on the discovery and development of selective cancer therapies, announced that it has accepted an acquisition offer from Concentra Biosciences, an investment firm under the hedge fund Tang Capital Partners. Through this deal, Concentra will acquire Elevation’s shares for $0.36 per share in cash, valuing the company at approximately $22 million.
Additionally, shareholders will receive a non-tradable Contingent Value Right (CVR), granting them the right to receive 80% of the proceeds from any future transaction involving EO-1022—Elevation's only remaining drug candidate—as well as any residual cash exceeding a $26.4 million threshold, within a specified time frame.
The acquisition offer has received full support from Elevation's Board of Directors and is expected to launch before June 23 and close in July, pending shareholder approval. The company agreed to the acquisition following a nearly 90% drop in its stock price over the past year.
In March of this year, Elevation announced the termination of development for EO-3021, a Claudin18.2 ADC drug licensed from CSPC Pharmaceutical Group in a deal worth nearly $1.2 billion. The decision to halt development was based on Phase I clinical trial data. While EO-3021 showed good safety, its efficacy did not demonstrate competitiveness compared to other Claudin18.2 ADCs. Its ORR was only 22.2%, significantly lower than the earlier reported 47.1%, rendering further development unjustifiable.
According to the press release, Elevation’s only remaining drug candidate is EO-1022, a HER3-targeted ADC for solid tumors, currently in preclinical development. In December of last year, the company also incorporated Synaffix’s technology platform to enhance the project. Before accepting Concentra’s acquisition offer, Elevation stated plans to present preclinical data at the 2025 AACR Annual Meeting and submit an Investigational New Drug (IND) application for EO-1022 in 2026.
Additionally, Elevation Oncology has opted to repay a $30 million term loan early, demonstrating its proactive financial management. The company is also undergoing a significant workforce reduction of approximately 70%, with associated costs expected to be around $3 million.
These strategic moves, including staff changes and debt repayment, indicate that Elevation Oncology is actively reallocating resources and exploring strategic alternatives to maximize shareholder value. Investors will be closely watching the progress of EO-1022, as well as potential partnerships or transactions. The company’s current cash reserves are expected to support operations through the second half of 2026, providing a degree of financial stability amid these developments.
